Evidence map›Paper›PMID 34697026›Full record

ArticleAnnals of the rheumatic diseases2022

Anti-ANP32A antibodies in systemic sclerosis.

Rachel Wallwork, Livia Casciola-Rosen, Ami A Shah

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Rachel WallworkDepartment of Medicine/Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-0073-7438
Livia Casciola-RosenDepartment of Medicine/Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Ami A ShahDepartment of Medicine/Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA Ami.Shah@jhmi.edu.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Antony Rosen · 2016 to 2026
$8.9M
Multidisciplinary Rheumatology Training ProgramT32AR048522 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, LIVIA A CASCIOLA-ROSEN · 2003 to 2026
$6.4M
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to CancerR01AR073208 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI LIVIA A CASCIOLA-ROSEN, Ami Aalok Shah · 2018 to 2026
$5.2M
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in sclerodermaK24AR080217 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Ami Aalok Shah · 2022 to 2026
$847k
NIAMS NIH HHS K24 AR080217NIAMS NIH HHS P30 AR070254NIAMS NIH HHS R01 AR073208NIAMS NIH HHS T32 AR048522
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAutoantibodiesAutoantigensCarcinoma, Squamous CellFemaleHumansMaleMiddle AgedNuclear ProteinsRNA-Binding ProteinsScleroderma, SystemicSkin NeoplasmsANP32A protein, humanAutoantibodiesAutoantigensNuclear ProteinsRNA-Binding Proteinsautoantibodiesautoimmune diseasessclerodermasystemic

Identifiers

PMID34697026
PMCPMC8961456
OpenAlexW3209677802

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.